What’s the End Game? Rethinking Prostate Cancer Screening, Biopsy, and Treatment

Is the Current Prostate Cancer Strategy Helping Men or Hurting Them?

Most men believe they are making rational decisions when it comes to prostate cancer. They believe they are following the science, trusting the experts, and doing what is necessary to protect themselves. The process appears logical. PSA rises. Concern follows. A urology appointment is scheduled. A prostate biopsy is recommended. Cancer is identified. Surgery, radiation, hormone therapy, or active surveillance enter the conversation. The pathway feels systematic, modern, and evidence-based.

But there is one question almost nobody asks.

Where is this path actually leading?

Not what happens next week. Not what the next PSA value will be. Not what the MRI will show. The real question is much larger than that. What is the end game?

That question should matter to every man. Unfortunately, most men never ask it because fear enters the conversation long before thoughtful analysis does. Once fear takes over, the focus narrows. The objective becomes simple. Remove the cancer. Kill the cancer. Treat the cancer. Aggressively if necessary.

But what if the strategy itself deserves more scrutiny?

What if the path men are pushed onto often creates more harm than benefit?

That is not an easy conversation to have. It challenges assumptions that have been deeply ingrained in modern medicine. But difficult questions are often the ones worth asking.

If the end result of treatment is a man who survives but loses vitality, sexual function, physical strength, independence, and quality of life without clear evidence of improved survival, then we need to be honest enough to ask whether the strategy makes sense.

That is the uncomfortable conversation modern prostate cancer care largely avoids.

The Uncomfortable Truth About Prostate Cancer

The average man hears the word cancer and immediately thinks of something aggressive, dangerous, and rapidly progressive. That reaction is understandable. Most cancers carry enormous emotional weight. But prostate cancer is different, and understanding that difference is critical.

Autopsy studies have been showing us something extraordinary for decades. A significant percentage of men over the age of fifty already have abnormal prostate cells. By advanced age, most men do. Yet the overwhelming majority of these men never suffer meaningful harm from those cells. They never develop symptoms. They never develop metastatic disease. They never die from prostate cancer.

Think about that carefully.

If abnormal prostate cells are so common, and if most men never suffer harm from them, then what exactly are we detecting when we diagnose prostate cancer?

That question changes everything.

I often refer to these as atypical dormant cells. These are abnormal cells that may remain biologically quiet for years or even decades. They may exist without progressing. They may never threaten life. They may never require aggressive intervention. Yet once they are identified and labeled as cancer, the emotional trajectory changes immediately.

Fear enters the room.

And once fear enters, logic often exits.

This is one of the central problems with modern prostate cancer screening. The issue is not necessarily screening itself. The issue is what happens after screening.

The PSA test is not the enemy. PSA is simply information. It is a signal. It is a marker. It is not a diagnosis. It is certainly not a treatment plan. Unfortunately, many men hear the words “Your PSA is elevated” and immediately assume they are headed toward biopsy, diagnosis, and treatment.

That assumption deserves to be challenged.

When Detection Becomes the Problem

One of the greatest assumptions in modern medicine is that earlier detection automatically leads to better outcomes. On the surface, this sounds entirely reasonable. Find disease early, intervene early, and improve survival. That logic has driven much of modern screening and diagnostic medicine, particularly in prostate cancer.

The problem is that reality is often far more complicated.

Modern medicine has become extraordinarily skilled at detecting abnormalities. We can identify smaller lesions, earlier changes, and more subtle markers than ever before. This technological advancement is almost always presented as progress, and in some cases it certainly is. But better detection does not automatically translate into better outcomes. That distinction is critically important, and it is where the logic surrounding prostate cancer often begins to break down. ProtecT Trial – 15-Year Outcomes (NEJM) PIVOT Trial (NEJM)

The issue is not whether we can detect abnormalities within the prostate. We clearly can. The real challenge is determining which abnormalities are clinically meaningful and which are not. That is a much more difficult question, and unfortunately one that medicine still struggles to answer with confidence.

For decades, the dominant narrative has been straightforward: detect prostate cancer early, treat it aggressively, and save lives. It sounds logical, but prostate cancer has always resisted simplistic thinking. Not every lesion is dangerous. Not every abnormality is destined to progress. Not every cancer diagnosis leads to suffering or death.

This is where uncertainty enters the conversation, and medicine has always been uncomfortable with uncertainty. Patients do not like uncertainty either. Uncertainty creates anxiety, and anxiety creates pressure to act. Do something. Remove something. Treat something.

But action itself carries consequences.

That is the part of the conversation that is often minimized or ignored. Men are understandably focused on survival. Physicians are understandably focused on reducing risk. Yet far less attention is often given to what life looks like after intervention. What happens to function? What happens to vitality? What happens to quality of life?

That is where the real conversation begins, because finding an abnormality is only useful if acting on that information leads to a meaningful improvement in outcomes. If detection simply leads to more procedures, more side effects, and more harm without significantly improving survival, then we need to be willing to question whether detection alone is truly helping the patient.

Does Prostate Cancer Treatment Improve Survival?

This is perhaps the most uncomfortable question in prostate cancer care.

Most men assume surgery or radiation clearly improves survival. They believe removing the prostate or radiating the tumor significantly changes long-term mortality. Many physicians operate under the same assumption.

The evidence is far more complicated.

The 15-year ProtecT trial produced deeply uncomfortable data for advocates of aggressive conventional treatment. Men assigned to active monitoring, surgery, and radiation had similarly low prostate cancer-specific mortality. Think about that for a moment. Across all three groups, survival remained remarkably high. ProtecT Trial (NEJM)

The PIVOT trial reached similar conclusions. For many men with localized prostate cancer, surgery offered little to no meaningful survival advantage compared with observation. PIVOT Trial (NEJM)

That should concern every man considering aggressive treatment.

To be clear, aggressive prostate cancer exists. Some men absolutely require intervention. I am not arguing otherwise. But the assumption that every detected prostate cancer benefits from aggressive treatment is simply not supported by the evidence.

What we do know with certainty is that treatment carries real harm.

Urinary incontinence. Erectile dysfunction. Loss of libido. Fatigue. Depression. Muscle loss. Weight gain. Loss of confidence. Loss of identity.

These are not rare complications. These are common consequences.

And this brings us back to the same question.

What is the end game?

If a man lives roughly the same number of years but loses function, vitality, and quality of life along the way, was that truly a better outcome?

That is not a rhetorical question. That is the central question.

Why Prostate Biopsy Deserves More Scrutiny

One of the most common questions I hear from men is straightforward: Should I get a prostate biopsy? For many, the assumption is that biopsy is simply the next logical step. PSA rises, concern follows, and biopsy is presented as routine, almost automatic. The recommendation is often delivered in such a way that declining the procedure feels irresponsible or reckless.

I strongly disagree with how casually this is often presented.

A prostate biopsy is not a trivial event. It is an invasive procedure with real physical and psychological consequences. There is pain, bleeding, infection risk, urinary retention, and hospitalization. In some cases, serious infections and sepsis occur. These complications are not theoretical concerns. They are well documented and occur every day in clinical practice. Prostate Biopsy Complications Study

But the physical risks, while important, are only part of the story.

The greater consequence often begins the moment the pathology report comes back.

Cancer.

That single word changes everything.

Even if the findings suggest low-grade disease. Even if the lesion appears slow-growing. Even if the biology suggests it may never become clinically significant. Once the diagnosis is made, the emotional landscape shifts dramatically.

Fear enters the room.

And once fear enters, decision-making changes.

Men who felt relatively calm before biopsy often begin to panic. Families panic. Spouses panic. Adult children panic. Pressure builds quickly, and suddenly the conversation shifts from thoughtful analysis to urgent action. The overwhelming feeling becomes that something must be done immediately.

This is where logic often begins to break down.

The man who felt healthy yesterday may now feel as though his life is in immediate danger. He often feels pushed toward major decisions before fully understanding what the diagnosis actually means, what the true risks are, and what the long-term consequences of treatment may be.

This is precisely why I believe prostate biopsy deserves far more thoughtful discussion than most men are given.

The real question is not whether a biopsy can identify cancer. Of course it can. The more important question is whether identifying that cancer meaningfully improves the final outcome. That is a very different question, and one that deserves far more attention than it currently receives.

The Hidden Cost of Hormone Suppression

This brings us to one of the most concerning areas in modern prostate cancer treatment: androgen deprivation therapy, commonly referred to as ADT or hormone therapy. While the name sounds relatively benign, the reality is far more serious. ADT works by dramatically suppressing testosterone levels, essentially creating a state of chemical castration. That phrase makes many people uncomfortable, but perhaps it should, because the physiological consequences are profound.

The logic behind ADT appears straightforward. Prostate cancer cells often respond to androgens, particularly testosterone. Lower testosterone aggressively, and cancer growth may slow. The theory is simple. The biological consequences are not.

The problem is that testosterone is not merely a hormone related to sexual function. Testosterone is deeply tied to nearly every aspect of male vitality. It influences muscle mass, energy, metabolism, motivation, mood, cognition, cardiovascular health, and physical resilience. Remove it, and predictable consequences follow.

Not occasionally. Predictably.

Men undergoing ADT commonly experience severe fatigue, loss of muscle mass, increased body fat, weight gain, insulin resistance, depression, cognitive decline, reduced motivation, and profound loss of libido. Sexual function often declines dramatically or disappears entirely. Many men describe feeling as though they have become a different person altogether. ADT Side Effects Review

The metabolic consequences are equally troubling. Studies have shown increased risks of diabetes, cardiovascular disease, osteoporosis, and fractures in men receiving androgen deprivation therapy. ADT Metabolic Risk Study

Think carefully about what this means.

We are often imposing predictable and significant harm in exchange for benefits that are not always clear, durable, or meaningful in terms of overall survival and quality of life.

That should concern both physicians and patients.

To be clear, I am not suggesting there is never a role for ADT. There are clinical scenarios where hormone suppression may be appropriate. The problem is not that ADT exists. The problem is how casually its consequences are often presented during the decision-making process.

Too often, the discussion becomes narrowly focused on suppressing PSA, shrinking lesions, or slowing disease markers, while insufficient attention is given to the human cost of that intervention. This is where modern medicine often falls into a dangerous trap. We become so focused on treating the disease that we lose sight of the person living with the treatment.

Men are not PSA values. Men are not lab markers. Men are human beings with lives, families, responsibilities, goals, and identities. That perspective should remain central to every treatment decision, especially when the treatment itself carries such profound consequences.

The Danger of Treating Numbers Instead of Men

One of the greatest weaknesses in modern medicine is its growing obsession with numbers. Lower the PSA. Lower the cholesterol. Lower the glucose. Lower the marker. Numbers matter, of course. They provide useful information and can help guide decision-making. But numbers are not the ultimate objective. Health is the objective. Function is the objective. Vitality is the objective.

This distinction is critical because modern medicine often confuses improving a number with improving a human life. Sometimes lowering a marker leads to better outcomes. Sometimes it does not. That is where the logic often breaks down. Medicine has become increasingly reliant on surrogate endpoints, measurable laboratory values that are assumed to predict meaningful health outcomes. But a better lab value does not always translate into better health, better function, or longer life. JAMA on Surrogate End Points

This problem is particularly evident in prostate cancer care. A PSA rises and panic often follows. Treatment is escalated. Hormones are suppressed. Procedures are recommended. The focus quickly shifts toward lowering PSA at all costs. But lowering PSA is not necessarily the same as improving survival, preserving function, or protecting quality of life.

The long-term data should force us to think more critically. The ProtecT trial demonstrated remarkably low prostate cancer mortality across active monitoring, surgery, and radiation groups despite dramatically different treatment strategies. ProtecT Trial (NEJM) That finding should cause every physician and every patient to pause and ask a difficult question: what exactly are we trying to optimize?

I have seen too many men aggressively treated based primarily on numbers while their overall vitality steadily declines. They become weaker, more fatigued, less functional, and less resilient. They lose muscle mass. They gain fat. Their energy drops. Their mental clarity suffers. Their lab values may look improved on paper, yet the person sitting in front of you is clearly deteriorating.

What exactly are we calling success?

That question deserves honest reflection because medicine should never lose sight of the bigger picture. A lower PSA may look reassuring on paper, but if the cost is profound loss of vitality, function, and quality of life, then we need to ask whether we are truly helping the patient or merely improving a number.

What Is the Smarter Path Forward?

The answer is not denial. The answer is not pretending aggressive prostate cancer does not exist, nor is it avoiding information or ignoring risk. The smarter path is not about doing less simply for the sake of doing less. It is about making better decisions. That begins by rejecting fear-based medicine.

Fear is one of the most powerful forces in prostate cancer care, and unfortunately, it drives many of the worst decisions. Fear creates urgency where urgency may not exist. Fear narrows perspective and pushes men toward irreversible interventions before they fully understand the long-term consequences. Once fear takes hold, thoughtful decision-making becomes much more difficult.

The smarter path begins with clarity. That means slowing down long enough to understand the full picture. Men need to understand their PSA trend, not just a single PSA value. They need to understand their MRI findings, overall health, metabolic status, hormone profile, symptoms, and true level of risk. Most importantly, they need to recognize that prostate health does not exist in isolation.

The prostate is not separate from the rest of the body. Inflammation matters. Metabolic dysfunction matters. Hormonal status matters. Muscle mass matters. Cardiovascular health matters. Insulin resistance matters. These factors are deeply interconnected because the body functions as an integrated system, not as isolated organs operating independently.

This is why I believe prostate cancer should be approached through a broader and more thoughtful framework. The goal should not simply be suppressing numbers or reacting emotionally to fear-driven narratives. The real objective is preserving vitality, strength, function, and quality of life while intelligently managing risk.

That requires thoughtful surveillance, strategic monitoring, and deliberate decision-making. Not passivity. Not panic. Strategy. That is what intelligent prostate care should look like.

The Question Every Man Must Ask

Before agreeing to a prostate biopsy, surgery, radiation, or hormone suppression, every man should stop and ask one simple but profoundly important question: What is the end game? Not what happens next week. Not what the next PSA result shows. Not what procedure is being recommended today. The real question is where this path ultimately leads.

That question changes everything because it forces men to think beyond the immediate fear of a diagnosis and toward the long-term consequences of their decisions. The ultimate goal should never be survival at any cost. Delaying death is a worthy pursuit, but not if the price is sacrificing the very things that make life meaningful. Strength matters. Vitality matters. Independence matters. Dignity matters. Quality of life matters.

We are all ultimately mortal. None of us escapes that reality. The objective is not immortality. The objective is to live as long as possible with strength, clarity, resilience, and purpose. That is the real end game.

This is why every major decision in prostate cancer deserves careful thought and honest scrutiny. Men should understand not only the potential benefits of treatment, but also the costs, tradeoffs, and long-term consequences. Too often, fear drives men toward irreversible decisions before they fully understand the path they are choosing.

That is the central problem.

Most men are focused on the next step. The next PSA. The next MRI. The next appointment. The next procedure. But very few stop to ask the question that matters most.

Where does this path actually lead?

That question changes everything.

Because the ultimate goal should not be survival at any cost. The real goal is to preserve strength, vitality, function, independence, and quality of life for as long as possible. Delaying death is a worthy pursuit, but not if the price is sacrificing the very things that make life worth living.

Sometimes the smartest decision in medicine is not what you choose to do next.

Sometimes the smartest decision is what you choose not to do.

To hear Dr. Petteruti’s full discussion on this topic, watch the complete podcast:What’s the End Game? Rethinking Prostate Cancer Screening and Strategy